Vosoritide
Sponsors
Andrew Dauber, BioMarin Pharmaceutical, Roopa Kanakatti Shankar, MBBS, MS
Conditions
AchondroplasiaHypochondroplasiaShort StatureTurner Syndrome
Phase 2
Vosoritide for Selected Genetic Causes of Short Stature
Active, not recruitingNCT04219007
Start: 2020-08-04End: 2035-06-01Updated: 2026-03-18
A Clinical Trial to Evaluate Safety of Vosoritide in At-risk Infants With Achondroplasia
Active, not recruitingNCT04554940
Start: 2020-10-10End: 2027-12-01Updated: 2026-03-13
Vosoritide for Short Stature in Turner Syndrome
RecruitingNCT05849389
Start: 2024-04-12End: 2026-09-30Target: 20Updated: 2024-06-24
A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months
RecruitingNCT07126262
Start: 2025-07-30End: 2028-06-30Target: 60Updated: 2026-03-31
Phase 3
Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia
Active, not recruitingNCT06455059
Start: 2024-06-17End: 2026-08-01Target: 80Updated: 2026-01-20
Long-Term Extension Study of Vosoritide to Treat Children With Hypochondroplasia
Enrolling by invitationNCT07073014
Start: 2025-06-20End: 2044-10-01Target: 140Updated: 2026-09-09